Vanguard Global Advisers
BIO icon

Vanguard Global Advisers’s Bio-Rad Laboratories Class A BIO Stock Holding History

Vanguard Global Advisers’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Sell
8,356
-348
-4% -$98.7K ﹤0.01% 1129
2026
Q1 		$2.43M Buy
+8,704
New +$2.51M ﹤0.01% 1066

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Global Advisers's BIO Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Bio-Rad Laboratories Class A (BIO) stake by 4% in Q2 2026, selling an estimated $98.7K and leaving 8,356 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1129.

Vanguard Global Advisers first reported a position in BIO in Q1 2026 and has held it in 2 quarters since. 393 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Vanguard Global Advisers held 8,356 shares of Bio-Rad Laboratories Class A worth $2.45M as of Q2 2026.
  • Vanguard Global Advisers sold 348 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $98.7K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1129 holding.
  • Vanguard Global Advisers first reported a position in Bio-Rad Laboratories Class A in Q1 2026 and has held it in 2 quarters since.
  • 393 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.